Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,213 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genes Clear all
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study Using Rexin-G for Sarcoma

NCT00505713
View directory record Official record
Conditions
Sarcoma
Interventions
Rexin-G
Genetic
Lead sponsor
Epeius Biotechnologies
Industry
Eligibility
10 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
San Marino, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 24, 2026, 5:31 PM EDT
Not listed No phase listed Observational

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

NCT04060641
View directory record Official record
Conditions
Hypertension
Interventions
Geneticure for RDN Genetic Panel
Genetic
Lead sponsor
Geneticure, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 24, 2026, 5:31 PM EDT
Completed No phase listed Observational

Evaluation of Blood Vessel Formation in Endocrine Tumors

NCT00923780
View directory record Official record
Conditions
Lesions
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 5:31 PM EDT
Terminated Phase 1 Interventional

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861
View directory record Official record
Conditions
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
Interventions
18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography, Filgrastim, Fludarabine, Leukapheresis, Plerixafor, Positron Emission Tomography
Other · Biological · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 24, 2026, 5:31 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

NCT07775313
View directory record Official record
Conditions
WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
Interventions
Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

NCT00031083
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions
Interferon-beta
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 24, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

NCT02781480
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
AAV RPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 24, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions
Ad2/HIF-1α/VP16, Saline (Placebo Control)
Biological · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 24, 2026, 5:31 PM EDT
Terminated No phase listed Observational

Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

NCT00899860
View directory record Official record
Conditions
Kidney Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 5:31 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

NCT03374202
View directory record Official record
Conditions
HIV-1 Infected Adults With Controlled Viremia
Interventions
VRC-HIVAAV070-00-GT (AAV8-VRC07)
Genetic
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 24, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Gene Expression, Meditative Movement, and Emotional Distress (GME)

NCT04213872
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Meditative Movement
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
45 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 24, 2026, 5:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

NCT02599922
View directory record Official record
Conditions
Achromatopsia
Interventions
rAAV2tYF-PR1.7-hCNGB3
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 24, 2026, 5:31 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

NCT05778877
View directory record Official record
Conditions
Methylmalonic Acidemia (MMA)
Interventions
SEL-302
Drug
Lead sponsor
Selecta Biosciences, Inc.
Industry
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 24, 2026, 5:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

NCT05987956
View directory record Official record
Conditions
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Interventions
ALECENSA - alectinib hydrochloride capsule
Drug
Lead sponsor
Medicine Invention Design, Inc
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Doral, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Immune Response to Bacterial Infection

NCT00546195
View directory record Official record
Conditions
Prematurity, Histologic Chorioamnionitis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 5:31 PM EDT
Completed No phase listed Observational

Imaging and Genetic Investigation of Learning and Decision Making

NCT01950377
View directory record Official record
Conditions
Polymorphism- Genetic, Reward Mediating System
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 24, 2026, 5:31 PM EDT
Recruiting No phase listed Observational

Boston Birth Cohort Study

NCT03228875
View directory record Official record
Conditions
Maternal Health, Child Health, Pregnancy Complications, Birth Outcome, Adverse
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
0 Years to 50 Years
Enrollment
24,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Echocardiography Test, Ipilimumab, Nivolumab, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Austin, Texas • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Active, not recruiting No phase listed Observational

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

NCT06855394
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Recruiting Phase 4 Interventional

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

NCT07531251
View directory record Official record
Conditions
Barth Syndrome
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
5 Years to 55 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Genes, Soy Isoflavones, and Virus

NCT07828405
View directory record Official record
Conditions
Wheezing
Interventions
Soy Isoflavone Nutritional Supplements
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months to 24 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 24, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection From Individuals With Lung Disease for Genetic Studies

NCT00362739
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
3,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 24, 2026, 5:31 PM EDT